Skip to main content
SpringerLink
Log in

Development and Characterization of a Progressive Series of Mammary Adenocarcinoma Cell Lines Derived from the C3(1)/SV40 Large T-antigen Transgenic Mouse Model

  • Published:
Breast Cancer Research and Treatment Aims and scope Submit manuscript

Abstract

We have developed four new mammary adenocarcinoma cell lines from the C3(1)/SV40 Large T-antigen (Tag) transgenic mouse model: M28N2 and M27H4 (weakly tumorigenic), M6 (carcinoma), and M6C (metastatic). The C3(1) promoter directs Tag expression to the mammary epithelium and 100% of female C3(1)/Tag transgenic mice develop mammary adenocarcinoma in a predictable and progressive manner. The cell lines we developed from this model are demonstrated to be of epithelial origin and display growth rates, both in vitro and following subcutaneous inoculation into nude mice, that are consistent with their representative stage of tumor progression. The more tumorigenic cell lines, M6 and M6C, both express the sodium/iodide symporter, a mammary carcinoma cell marker with potential therapeutic and diagnostic applications. All of the cell lines express estrogen receptor (ER) α and ER β mRNA, and Western blot analysis demonstrates that the ER α protein is down-regulated in the M6 and M6C cell lines. M28N2 cells also express progesterone receptor (PgR), which is very unusual in a mouse mammary carcinoma cell line. In addition, all of the cell lines display growth inhibition when plated in media supplemented with charcoal-stripped fetal calf serum (CS FBS). When CS FBS is supplemented with β estradiol or the progestin MPA, no significant difference in growth rates is observed relative to growth in CS FBS. The development and characterization of a progressive series of new mammary carcinoma cell lines will aid in the study of mammary carcinoma progression both in vitro and in vivo.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Harris JR, Morrow M, Bonadonna G. In: DeVita VT, Hellman S, Rosenberg SA (eds) Cancer: Principles and Practice of Oncology. Lippincott, Philadelphia, 1993, pp 1264-1332

    Google Scholar 

  2. Maroulakou IG, Anver M, Garrett L, Green JE: Prostate and mammary adenocarcinoma in transgenic mice carrying a rat C3(1) simian virus 40 large tumor antigen fusion gene. Proc Natl Acad Sci USA 91: 11236-11240, 1994

    Google Scholar 

  3. Parker MG, White R, Hurst H, Needham M, Tilly R: Prostatic steroid binding protein. Isolation and characterization of C3 genes. J Biol Chem 258: 12-15, 1983

    Google Scholar 

  4. Green JE, Shibata M, Yoshidome K, Liu M, Jorcyk CL, Anver MR, Wigginton JM, Wiltrout R, Shibata E, Kaczmarczyk S, Wang W, Liu Z, Calvo A, Couldrey C: The C3(1)/SV40 Tantigen transgenic mouse model of mammary cancer: ductal epithelial cell targeting with multistage progression to carcinoma. Oncogene 19: 1020-1027, 2000

    Google Scholar 

  5. Jorcyk CL, Liu M, Shibata M, Maroulakou IG, Komschlies KL, McPhaul MJ, Resau JH, Green JE: Development and characterization of a mouse prostate adenocarcinoma cell line: ductal formation determined by extracellular matrix. The Prostate 34: 10-22, 1998

    Google Scholar 

  6. Soares CR, Shibata M, Green JE, Jorcyk CL: Development of PIN and prostate adenocarcinoma cell lines: a model system for multistage tumor progression. Neoplasia 4: 112-120, 2002

    Google Scholar 

  7. Pittius CW, Sankaran L, Topper YJ, Henninghausen L: Comparison of the regulation of the whey acidic protein gene with that of a hybrid gene containing the whey acidic protein gene promoter in transgenic mice. Mol Endocrinol 2: 1027-1232, 1989

    Google Scholar 

  8. Cato AC, Weinmann J, Mink S, Ponta H, Henderson D, Sonnenberg A: The regulation of expression of mouse mammary tumor virus DNA by steroid hormones and growth factors. J Steroid Biochem 34: 139-143, 1989

    Google Scholar 

  9. Mietz JA, Unger T, Huibregtse JM, Howly PM: The transcriptional transactivation function of wild-type p53 is inhibited by SV40 large T antigen and by HPV-16 E6 oncoprotein. EMBO J 11: 5013-5020, 1992

    Google Scholar 

  10. Dyson N, Buchkovich K, Whyte P, Harlow E: The cellular 107K protein that binds to adenovirus E1A also associates with the large T antigens of SV40 and JC virus. Cell 58: 249-255, 1989

    Google Scholar 

  11. Osborne RJ, Merlo GR, Mitsudomi T, Venesio T, Liscia DS, Cappa AP, Chiba I, Takahashi T, Nau MM, Callahan R et al.: Mutations in the p53 gene in primary human breast cancers. Cancer Res 51: 6194-6198, 1991

    Google Scholar 

  12. Cox LA, Chen G, Lee EY: Tumor suppressor genes and their roles in breast cancer. Breast Cancer Res Treat 32: 19-38, 1994

    Google Scholar 

  13. Ludlow JW: Interactions between SV40 large-tumor antigen and the growth suppressor proteins pRB and p53. FASEB J 7: 866-871, 1993

    Google Scholar 

  14. Yoshidome K, Shibata M, Maroulakou IG, Liu M, Jorcyk CL, Gold LG, Welch VN, Green JE: Genetic alterations in the development of mammary and prostate cancer in the C3(1)/Tag transgenic mouse model (review). Int J Oncol 12: 449-453, 1998

    Google Scholar 

  15. Yoshidome K, Shibata M, Couldrey C, Korach KS, Green JE: Estrogen promotes mammary tumor development in C3(1)/SV40 large T-antigen transgenic mice: paradoxical loss of estrogen receptor α expression during tumor progression. Cancer Res 60: 6901-6910, 2000

    Google Scholar 

  16. Guiochon-Mantel A, Milgrom E. In: Manni A (ed.) Endocrinology of Breast Cancer. Humana, New Jersey, NJ, 1999, pp 245-259

    Google Scholar 

  17. Tazebay UH, Wapnir IL, Levy O, Dohan O, Zuckier LS, Zhao Q, Deng H, Amenta PS, Fineberg S, Pestell RG, Carrasco N: The mammary gland iodide transporter is expressed during lactation and in breast cancer. Nat Med 6: 871-878, 2000

    Google Scholar 

  18. Carrasco N: Iodide transport in the thyroid gland. Biochim Biophys Acta 1154: 65-82, 1993

    Google Scholar 

  19. Liu M, Von Lintig FC, Liyanage M, Shibata M, Jorcyk CL, Ried T, Boss GR, Green JE: Amplification of Ki-ras and elevation of MAP kinase activity during mammary tumor progression in C3(1)/SV40 Tag transgenic mice. Oncogene 17: 2403-2411, 1998

    Google Scholar 

  20. Shibata M, Yoshidome K, Shibata E, Jorcyk CL, Green JE: Suppression of mammary carcinoma growth in vitro and in vivo by inducible expression of the Cdk inhibitor p21. Cancer Gene Therapy 1: 1-10, 2000

    Google Scholar 

  21. Shibata M, Maroulakou IG, Jorcyk CL, Gold L, Ward JM, Green JE: p53-independent apoptosis during mammary tumor progression in C3(1)/SV40 large T antigen transgenic mice: suppression of apoptosis during the transition from preneoplasia to carcinoma. Cancer Res 56: 2998-3003, 1996

    Google Scholar 

  22. Shibata MA, Liu ML, Knudson MC, Shibata E, Yoshidome K, Bandey T, Korsmeyer SJ, Green JE: Haploid loss of bax leads to accelerated mammary tumor development in C3(1)/SV40 Tag transgenic mice: reduction in protective apoptotic response at the preneoplastic stage. EMBO J 18: 2692-2701, 1999

    Google Scholar 

  23. Wigginton JM, Park JW, Gruys ME, Young HA, Jorcyk CL, Back TC, Brunda MJ, Strieter RM, Ward J, Green JE, Wiltrout RH: Complete regression of established spontaneous mammary carcinoma and the therapeutic prevention of genetically programmed neoplastic transition by Il-12/pulse Il-2: induction of local T cell infiltration, Fas/Fas ligand gene expression, and mammary epithelial apoptosis. J Immunol 166: 1156-1168, 2001

    Google Scholar 

  24. Yokoyama Y, Green JE, Sukhatme VP, Ramakrishnan S: Effect of endostatin on spontaneous tumorigenesis of mammary adenocarcinoma in a transgenic mouse model. Cancer Res 60: 4362-4365, 2000

    Google Scholar 

  25. Welcsh PL, Mankoff DA: Taking up iodide in breast tissue. Nature (Lond.) 406: 688-689, 2000

    Google Scholar 

  26. Daniels GH, Haber DA: Will radioiodine be useful in treatment of breast cancer? Nat Med 6: 859-860, 2000

    Google Scholar 

  27. Roger P, Sahla ME, Makela S, Gustafsson JA, Baldet P, Rochefort H: Decreased expression of estrogen receptor-protein in proliferative preinvasive mammary tumors. Cancer Res 61: 2537-2541, 2001

    Google Scholar 

  28. Leygue E, Dotzlaw H, Watson PH, Murphy LC: Altered estrogen receptor α and β messenger RNA expression during human breast tumorigenesis. Cancer Res 58: 3197-3201, 1998

    Google Scholar 

  29. Jarvinen TA, Pelto-Huikko M, Holli K, Isola J: Estrogen receptor α is coexpressed with ER β and PR and associated with nodal status, grade, and proliferative rate in breast cancer. Am J Pathol 156: 29-35, 2000

    Google Scholar 

  30. Speirs V, Parkes AT, Kerin MJ, Walton DS, Carleton PJ, Fox JN, Atkin SL: Coexpression of estrogen receptor α and β: poor prognostic factors in human breast cancer? Cancer Res 59: 525-528, 1999

    Google Scholar 

  31. Lanari C, Luthy I, Lamb CA, Fabris V, Pagano E, Helguero LA, Sanjuan N, Merani S, Molinolo AA: Five novel hormone-responsive cell lines derived from murine mammary ductal carcinomas: in vivo and in vitro effects of estrogens and progestins. Cancer Res 61: 293-302, 2001

    Google Scholar 

  32. Wang W, Smith R, Burghardt R, Safe SH: 17β-Estradiolmediated growth inhibition ofMDA-MB-468 cell stably transfected with the estrogen receptor: cell cycle effects. Mol Cell Endocrinol 133: 49-62, 1997

    Google Scholar 

  33. Kordon E, Lanari C, Meiss R, Elizalde P, Charreau E, Pasqualini CD: Hormone dependence of a mouse mammary tumor line induced in vivo by medroxyprogesterone acetate. Breast Cancer Res Treat 17: 33-43, 1990

    Google Scholar 

  34. Brunner N, Spang-Thomsen M, Cullen K: The T61 human breast cancer xenograft: an experimental model of estrogen therapy of breast cancer. Breast Cancer Res Treat 39: 87-92, 1996

    Google Scholar 

  35. Read LD, Snider CE, Miller JS, Greene GL, Katzenellenbogen BS: Ligand-modulated regulation of progesterone receptor messenger ribonucleic acid and protein in human breast cancer cell lines. Mol Endocrinol 2: 263-271, 1988

    Google Scholar 

  36. Lapidus RG, Nass SJ, Davidson NE: The loss of estrogen and progesterone receptor gene expression in human breast cancer. J Mamm Gland Biol Neop 3: 85-94, 1998

    Google Scholar 

  37. Ross RK, Paganini-Hill A, Wan PC, Pike MC: Effect of hormone replacement therapy on breast cancer risk: estrogen versus estrogen plus progestin. J Natl Cancer Inst 92: 328-332, 2000

    Google Scholar 

  38. Shi YE, Liu YE, Lippman ME, Dickson RB: Progestins and antiprogestins in mammary tumour growth and metastasis. Hum Reprod 9(suppl. 1): 162-173, 1994

    Google Scholar 

  39. Sacco MG, Gribaldo L, Barbieri O, Turchi G, Zucchi I, Collatta A, Bagnasco L, Barone D, Montagna C, Villa A, Marafante E, Vezzoni P: Establishment and characterization of a new mammary adenocarcinoma cell line derived from MMTV neu transgenic mice. Breast Cancer Res Treat 47: 171-180, 1998

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Biology, Boise State University, Boise, ID, USA

    Ryan G. Holzer, Christina MacDougall, Gerry Cortright, Kristi Atwood & Cheryl L. Jorcyk

  2. Laboratory of Cell Regulation and Carcinogenesis, Center for Cancer Research, National Cancer Institute, National Institute of Health, Bethesda, MD, USA

    Jeffrey E. Green

Authors
  1. Ryan G. Holzer
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Christina MacDougall
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Gerry Cortright
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Kristi Atwood
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Jeffrey E. Green
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Cheryl L. Jorcyk
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Holzer, R.G., MacDougall, C., Cortright, G. et al. Development and Characterization of a Progressive Series of Mammary Adenocarcinoma Cell Lines Derived from the C3(1)/SV40 Large T-antigen Transgenic Mouse Model. Breast Cancer Res Treat 77, 65–76 (2003). https://doi.org/10.1023/A:1021175931177

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1023/A:1021175931177

Search

Navigation